Spruce Biosciences, Inc.

NASDAQ:SPRB

Biotechnology

Healthcare
$40.84 +5.07%

+$2.47 today

Market cap
$117.37M
Beta
3.20
P/E (TTM)
-1.9
EPS (TTM)
-$27.11
52W Low $7.00High $838.13

Volume 0.06M

Average 0.06M

SPRB Weighted Avg Shares (Diluted)

Average shares outstanding including dilutive securities, used to calculate diluted EPS.

Spruce Biosciences, Inc.NASDAQ: SPRB

Weighted Avg Shares (Diluted) · Q1 FY2026 · quarter ended Mar 2026

Weighted avg shares (diluted) growth accelerates

Q1 FY2026 weighted avg shares (diluted) of 1.37M shares rose 140.2% year over year, ahead of the +51.8% change in trailing-twelve-month weighted avg shares (diluted). Sequentially, it rose 79.0% from the prior quarter. Over 3 fiscal years it compounded at +7.8% a year.

Context

  • Weighted avg shares (diluted) increased in 2 of the last 3 fiscal years.
  • FY2025 was the highest annual figure in the 4 fiscal years shown.

What to watch

Whether quarterly growth of +140.2% holds above the trailing-twelve-month pace of +51.8%.

Sources:Income StatementText generated from reported figures; not investment advice.

Latest quarterMar 2026
1.37M+79.0% QoQ
Last fiscal yearDec 2025
766.6K+42.9% YoY
LTMMar 2026
827.01K+51.8% YoY
Weighted Avg Shares (Diluted) past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter+140.2%——
1 year+42.9%——
3-year CAGR+7.8%——
5-year CAGR——
10-year CAGR——

Weighted Avg Shares (Diluted) history

Shares · from the income statement

Latest · FY2025
766.6K USD
Year-over-year change
+42.9%
4-year CAGR
+6.0%

Weighted Avg Shares (Diluted) vs competitors

How SPRB compares with its peers on the latest reported figures

  • SPRB's LTM Mar 2026 weighted avg shares (diluted) of 827.01K shares is the lowest of the 9 companies compared; the peer median is 27.2M shares.
  • Its year-over-year change of +51.8% is the 4th highest of 9, against a peer median of +22.2%.
  • Over three fiscal years its annual growth of +7.8% compares with a peer median of +25.7%.
SPRB Competitors Peer median
Weighted Avg Shares (Diluted) for SPRB and competitors
Company Period LTM YoY 3-year CAGR
EQEquillium, Inc.LTM Mar 202664.9M +81.6%+39.7%
HOWLWerewolf Therapeutics, Inc.LTM Jun 202647.65M +7.1%+17.5%
OSTXOS Therapies IncorporatedLTM Mar 202631.25M -31.1%+8.2%
OTLKOutlook Therapeutics, Inc.LTM Mar 202628.35M +14.4%+33.9%
NRXPNRx Pharmaceuticals, Inc.LTM Mar 202626.06M +115.3%-31.2%
VTVTvTv Therapeutics Inc.LTM Mar 20267.87M +30.1%+63.7%
COEPCoeptis Therapeutics, Inc.LTM Mar 20264.68M -77.3%-33.3%
CUECue Biopharma, Inc.LTM Mar 20263.76M +80.5%+38.5%
SPRBSpruce Biosciences, Inc.LTM Mar 2026827.01K +51.8%+7.8%
Peer median (excluding SPRB) 27.2M+22.2%+25.7%

Competitors are the stored peer set for SPRB. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Income Statement

USD
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Revenue0010.09M4.91M0
Cost of Revenue00000
Gross Profit0010.09M4.91M0
Gross Margin——100.0%100.0%—
Research & Development30.7M35.2M49.43M46.42M19.52M
Selling, General & Admin11.37M12.09M12.65M14.64M16.99M
Operating Expenses42.07M47.28M62.08M61.06M36.51M
Depreciation & Amortization68K74K70K46K21K
EBITDA(41.88M)(45.69M)(47.37M)(52.68M)(38.86M)
EBITDA Margin——-469.5%-1072.8%—
Operating Income(42.07M)(47.28M)(51.99M)(56.15M)(36.51M)
Operating Margin——-515.3%-1143.4%—
Interest Income119K1.52M4.56M3.42M1.14M
Interest Expense345K420K483K307K90K
Other Income / Expenses(226K)1.1M4.07M3.12M(2.45M)
Income Before Tax(42.29M)(46.18M)(47.92M)(53.04M)(38.97M)
Pre-Tax Margin——-475.0%-1079.9%—
Income Tax Expense00000
Net Income(42.29M)(46.18M)(47.92M)(53.04M)(38.97M)
Net Margin——-475.0%-1079.9%—
EPS (Basic)(68.25)(72.00)(93.00)(96.75)(50.83)
EPS (Diluted)(68.25)(72.00)(93.00)(96.75)(50.83)
Weighted Avg Shares607.4K611.71K500.63K536.44K766.6K
Weighted Avg Shares (Diluted)607.4K611.71K500.63K536.44K766.6K

Spruce Biosciences, Inc.

NASDAQ:SPRB

Intrinsic Alpha fair value

Locked

Current Price

$40.84

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.